ARA-290 (Cibinetide) (10 mg Vial) Dosage Protocol
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin (EPO) that retains tissue-protective and anti-inflammatory effects without erythropoietic activity.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Route: Subcutaneous | Frequency: Daily during cycle | Half-life: ~2 hours
Standard Approach (2 mL = 8.00 mg/mL)
Reconstituting with 2 mL bacteriostatic water produces a concentration of 8.00 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.
| Phase / Protocol | Dose | U-100 Units | Volume | Doses per vial |
|---|---|---|---|---|
| Week 1 (titration) | 2 mg | 25 units | 0.25 mL | 8 doses |
| Weeks 2–8 (target) | 4 mg | 50 units | 0.50 mL | 4 doses |
Reconstitution Steps
- Wipe the vial stopper and BAC water vial with alcohol; let dry.
- Draw 2 mL of bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
- Gently swirl until fully dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2–8°C; use within 14 days.
Supplies Needed
Estimates for an 8-week and 12-week cycle at 4 mg per dose, daily during cycle (7 doses/week).
| Item | 8-Week Cycle | 12-Week Cycle |
|---|---|---|
| ARA-290 (Cibinetide) () vials | 14 vials | 21 vials |
| Insulin syringes (U-100) | 56 | 84 |
| Bacteriostatic water (10 mL) | 3 × 10 mL | 5 × 10 mL |
| Alcohol swabs | 1 × 100-pack | 2 × 100-pack |
Protocol Overview
ARA-290 (cibinetide) protocols target neuropathic pain and chronic inflammation. Phase 2 trials ran 28 days at 4 mg/day with significant pain reduction.
Dosing Protocol
Daily dosing:
- Standard (4 mg/day): Phase 2 trial dose.
Cycle: 28 days active per Phase 2 protocol; longer protocols (8–12 weeks) used in chronic-condition research.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 14 days, protect from light |
Important Notes
How This Works
ARA-290 is derived from helix B of EPO and binds the innate repair receptor (IRR — a tissue-protective receptor distinct from EPO's erythropoietic receptor). It produces anti-inflammatory and tissue-protective effects without raising hematocrit.
Potential Benefits & Side Effects
Potential Benefits
- Anti-inflammatory effects via IRR.
- Studied in diabetic neuropathy and sarcoidosis-related neuropathy.
- No erythropoietic effect — separate from EPO's blood effects.
Side Effect Profile
- Generally well-tolerated in trials.
- Mild injection-site reactions.
Lifestyle Factors
- Anti-inflammatory diet complements effects.
- Adequate B-vitamins support nerve health.
Injection Technique
- Subcutaneous, rotate sites.